ABG
IBIO icon

Ally Bridge Group’s iBio IBIO Stock Holding History

Ally Bridge Group’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$683K Buy
+390,147
New +$698K 0.6% 24

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ally Bridge Group's IBIO Position: Q2 2026 in Review

Ally Bridge Group opened a new position in iBio (IBIO) in Q2 2026: 390,147 shares worth $683K. The stake represents 0.6% of the portfolio and ranks #24 among its holdings.

55 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Ally Bridge Group held 390,147 shares of iBio worth $683K as of Q2 2026.
  • iBio was a new Ally Bridge Group position in Q2 2026.
  • iBio made up 0.6% of Ally Bridge Group's portfolio in Q2 2026, its #24 holding.
  • 55 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.